BioMarin (BMRN) director Ian T. Clark awarded 7,490 restricted stock units

Rhea-AI Filing Summary

CLARK IAN T reported acquisition or exercise transactions in this Form 4 filing.

BioMarin Pharmaceutical director Ian T. Clark received an equity grant. On June 2, 2026, he was awarded 7,490 restricted stock units tied to the company’s common stock, with no cash price per unit. Following this grant, he directly holds 14,490 common shares and units in total.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CLARK IAN T

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,490	$0.00	--

Holdings After Transaction: Common Stock — 14,490 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity grant size: 7,490 units Holdings after grant: 14,490 shares/units Grant price per unit: $0.0000 per share +1 more

4 metrics

Equity grant size 7,490 units Restricted stock units granted June 2, 2026

Holdings after grant 14,490 shares/units Total direct BioMarin common stock position after transaction

Grant price per unit $0.0000 per share Reported price for restricted stock unit award

Transaction code A Grant, award, or other acquisition of common stock

Key Terms

Restricted stock units, Common Stock, Grant, award, or other acquisition

3 terms

Restricted stock units financial

"Restricted stock units granted on June 2, 2026. Price not applicable."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CLARK IAN T

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC

770 LINDARO STREET

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		A		7,490	A	$0(1)	14,490	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units granted on June 2, 2026. Price not applicable.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BioMarin (BMRN) director Ian T. Clark report in this Form 4?

Ian T. Clark reported receiving 7,490 restricted stock units in BioMarin common stock as an equity award on June 2, 2026. The units were granted at no cash purchase price and increased his direct holdings to 14,490 common shares and units in total.

How many BioMarin (BMRN) shares does Ian T. Clark hold after this transaction?

After the June 2, 2026 award, Ian T. Clark directly holds 14,490 shares and restricted stock units of BioMarin common stock. This figure reflects the updated ownership position reported in the Form 4 following the 7,490-unit equity grant.

What type of transaction is reported for BioMarin (BMRN) director Ian T. Clark?

The transaction is a grant or award acquisition of equity, coded “A” on the Form 4. It reflects 7,490 restricted stock units of BioMarin common stock granted as compensation, rather than an open-market purchase or sale at a stated share price.

Was there a purchase price for Ian T. Clark’s new BioMarin (BMRN) shares?

No cash purchase price applied to this award. The Form 4 shows a price per share of 0.0000, and the footnote clarifies these are restricted stock units granted on June 2, 2026, indicating a compensation-based equity grant instead of a market transaction.

Does this BioMarin (BMRN) Form 4 involve derivative securities or options?

No derivative securities are reported in this filing. The derivativeSummary section is empty, and the only transaction disclosed is a non-derivative equity grant of 7,490 restricted stock units linked to BioMarin common stock for director Ian T. Clark.